503A vs 503B: Which Compounding Pharmacy Does Your Business Actually Need?
Every GLP-1, peptide, TRT, or hormone program in the US runs on compounded medication at some point, and every compounded medication comes from one of two legal categories created by the Drug Quality and Security Act of 2013: a 503A compounding pharmacy or a 503B outsourcing facility. Founders treat this as pharmacist trivia until it decides something expensive — whether you can stock medication in advance, whether your pharmacy can ship to a new state, or why a batch got held. The distinction is simple once framed correctly: 503A compounds for a named patient under a prescription; 503B manufactures in bulk under FDA's manufacturing-style oversight, without patient-specific prescriptions.
This guide explains both models, when a telehealth or med spa business needs which, and the questions to ask a pharmacy partner before signing. This is general information, not legal advice.
Key takeaways
- 503A pharmacies compound patient-specific prescriptions under state board of pharmacy oversight and federal USP standards; they are the default engine of DTC telehealth, where every order is tied to an individual prescription anyway.
- 503B outsourcing facilities register with FDA, follow CGMP (current good manufacturing practice), and can produce large batches without patient-specific prescriptions — which is what clinics and med spas need for office-administered stock.
- The decision rule for founders: patient-specific mail-order model → 503A; in-office administration or stocked inventory → 503B (or both, as many scaled programs use).
- State licensing is per-state for 503A shipping: your pharmacy partner must hold a non-resident pharmacy license for every state you sell into, which is why multi-state programs need multi-pharmacy routing.
- Pharmacy quality varies enormously within both categories; the questions that matter are licensing coverage, sterile-compounding record, capacity, cold-chain logistics, and how fast they track FDA's compounding-list changes.
What is a 503A compounding pharmacy?
A 503A pharmacy is the traditional compounding pharmacy, named for section 503A of the Food, Drug & Cosmetic Act. Its defining feature: it compounds a medication for a specific patient, under a specific prescription, one order at a time (with limited anticipatory allowances). Oversight comes primarily from the state board of pharmacy, with compounding standards set by USP chapters (795 for non-sterile, 797 for sterile preparations).
For a DTC telehealth brand, this maps perfectly onto how the business already works: a provider reviews an intake, writes an individual prescription, and the 503A pharmacy compounds and ships that patient's semaglutide, testosterone, or eligible peptide with their name on the label. The 503A can only ship into states where it holds a license — the constraint that shapes multi-state operations more than any other.
What is a 503B outsourcing facility?
A 503B outsourcing facility, created by the 2013 law, is closer to a light manufacturer. It registers directly with FDA, follows CGMP, submits to FDA inspection, and can compound large batches without patient-specific prescriptions, selling to healthcare facilities for office use. That is the legal basis on which a med spa or clinic keeps medication in stock and administers it on site without a named-patient script for each vial in the fridge.
The trade-offs: 503B production runs are larger and less flexible (fewer custom formulations and dose variants), the facility list is far shorter than the 503A universe, and per-unit economics differ.
503A vs 503B side by side
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Compounds per | Named-patient prescription | Batch, no patient prescriptions required |
| Primary oversight | State board of pharmacy + USP standards | FDA registration + CGMP + inspections |
| Sells to | Patients (via prescription) | Healthcare facilities for office stock |
| Best for | DTC telehealth, mail-order, personalized dosing | Clinics/med spas administering on site, stocked inventory |
| Custom formulations | Flexible, patient-specific | Limited to produced batch SKUs |
| Multi-state shipping | Needs non-resident license per state | Facility-level distribution rules |
| Typical role in a telehealth brand | The core fulfillment engine | The office-use supplement for hybrid/clinic models |
Which one does your business model need?
DTC telehealth brand (mail-order): 503A, full stop. Every order in your funnel is already patient-specific, which is exactly the 503A model. What you actually need is several 503As with complementary state licenses and formulary strengths, plus routing logic that picks the right one per order — state licensure, product, and cold-chain capability. This is what OrbitRx does on MyOrbitHealth: e-prescriptions route via Surescripts across a LegitScript-certified pharmacy network so state coverage is a routing table, not a founder research project.
Med spa or clinic administering in-office: 503B for stocked, office-administered products (the vial you draw from for multiple patients), often alongside a 503A relationship for take-home patient-specific prescriptions. If you're adding telehealth revenue to a med spa, you'll likely run both rails — office stock via 503B, at-home programs via 503A.
Hybrid brands (clinic + national mail-order): both, deliberately. The failure mode is using the wrong rail — office stock sourced patient-by-patient from a 503A (operationally painful) or DTC orders pulled from unlabeled batch stock (a compliance problem).
The choice interacts with medication category too. GLP-1 compounding eligibility has shifted with FDA shortage-list changes, and peptide compounding depends on FDA's bulk-substance lists — both covered in our peptide legality guide and FDA peptide list. A good pharmacy partner tracks these lists daily; a bad one makes them your problem.
What should founders ask a compounding pharmacy partner?
- Which states are you licensed to ship into, today? Get the list in writing; it defines your launch map. Ask how new-state licensing gets handled and on whose timeline.
- What is your sterile-compounding inspection history? USP 797 compliance, recent state board actions, any FDA 483 observations (for 503Bs).
- What happens when FDA's lists change? Who notifies you, how fast, and what the substitution plan is for affected SKUs.
- Cold chain and turnaround: validated packaging for injectables, average days from e-script to shipment, and how failures are communicated.
- Pricing structure: per-unit pricing and whether the platform in the middle marks it up — medication economics move brand margins more than platform fees do, as our telemedicine startup costs breakdown shows.
- Capacity: what happens to your turnaround if your volume 10×es after a viral month.
A telehealth infrastructure partner should answer all six for its whole network, per state, before you sign — our roundup of the best white label telehealth platforms is a good place to start that shortlist — that's part of what you're buying.
Frequently asked questions
What is the difference between a 503A and 503B pharmacy?
A 503A pharmacy compounds medications for individual, named patients under prescriptions, overseen mainly by state boards of pharmacy. A 503B outsourcing facility registers with FDA, follows manufacturing-grade CGMP standards, and compounds large batches without patient-specific prescriptions for sale to healthcare facilities. Same molecules, different legal rails.
Does a telehealth business need a 503A or 503B pharmacy?
A direct-to-consumer telehealth brand needs 503A fulfillment, because every order is tied to an individual prescription and shipped to the patient. 503B matters when there is a physical clinic or med spa administering stocked medication on site. Scaled hybrid programs typically use both.
Can a 503A pharmacy ship to all 50 states?
Only if it holds a resident or non-resident pharmacy license for every destination state, which is rare. Most multi-state telehealth programs route orders across a network of 503A pharmacies whose combined licenses cover the map, choosing per order based on state, product, and cold-chain needs.
Is compounded semaglutide from a 503A pharmacy legal?
Compounding eligibility for GLP-1s has depended on FDA shortage-list status and related rules, which have changed over 2024–2026. When compounding is permitted, a 503A pharmacy may compound patient-specific prescriptions; when it is not, programs must use FDA-approved products. Any current answer should come with a date on it — ask your pharmacy partner for their current position in writing.
Who inspects compounding pharmacies?
State boards of pharmacy are the primary inspectors of 503A pharmacies, applying USP standards; FDA can and does act against 503As on contamination or scope violations. 503B outsourcing facilities are FDA-registered and FDA-inspected against CGMP, in addition to state requirements.
Get the pharmacy layer handled for you
MyOrbitHealth brands don't pick pharmacies from a directory: OrbitRx routes every prescription across a LegitScript-certified network of licensed compounding partners with cold-chain fulfillment, matched per order to state licensure and product — with 1,240+ board-certified providers upstream writing the patient-specific scripts that make the 503A model work. Book a demo to see the fulfillment map for your launch states.